UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Diagnosis and Management of Cerebral Amyloid Angiopathy: A Scientific Statement from the International CAA Association and the World Stroke Organization

Cordonnier, Charlotte; Klijn, Catharina; Smith, Eric Edward; Al-Shahi Salman, Rustam; Chwalisz, BK; van Etten, Ellis; Muir, Ryan T; ... Werring, David; + view all (2025) Diagnosis and Management of Cerebral Amyloid Angiopathy: A Scientific Statement from the International CAA Association and the World Stroke Organization. International Journal of Stroke 10.1177/17474930251365861. (In press). Green open access

[thumbnail of cordonnier-et-al-2025-diagnosis-and-management-of-cerebral-amyloid-angiopathy-a-scientific-statement-from-the.pdf]
Preview
PDF
cordonnier-et-al-2025-diagnosis-and-management-of-cerebral-amyloid-angiopathy-a-scientific-statement-from-the.pdf - Accepted Version

Download (1MB) | Preview

Abstract

Cerebral amyloid angiopathy (CAA) is a well-recognized and challenging disease for neurologists and other clinicians caring for the rapidly aging worldwide population. CAA is a major cause of spontaneous lobar intracerebral hemorrhage (ICH), and can also cause transient focal neurological episodes, and convexity subarachnoid hemorrhage, CAA associated ICH has a high mortality, morbidity, and recurrence rate. CAA can affect a wide range of clinical decisions including use of antithrombotic medications, safety for anti-β-amyloid peptide (Aβ) immunotherapy, and need for anti-inflammatory or immunosuppressive treatment. We present guidelines, intended to inform the approach to individuals with suspected CAA, written on behalf of the International CAA Association and the World Stroke Organization (WSO). We cover five areas selected for their relevance to practice: 1) Diagnosis, testing, and prediction of intracerebral hemorrhage risk; 2) Antithrombotic agents and vascular interventions; 3) Vascular risk factors and concomitant medications; 4) Treatment of CAA manifestations; and 5) Diagnosis and treatment of CAA-related inflammation and vasculitis. The statement has been reviewed and approved by the Executive Committee of the WSO, and the International CAA Association.

Type: Article
Title: Diagnosis and Management of Cerebral Amyloid Angiopathy: A Scientific Statement from the International CAA Association and the World Stroke Organization
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1177/17474930251365861
Publisher version: https://doi.org/10.1177/17474930251365861
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: Antithrombotic, Brain bleed, Brain microbleeds, Cerebral hemorrhage, Leukoaraiosis, MRI
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
URI: https://discovery.ucl.ac.uk/id/eprint/10211857
Downloads since deposit
82Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item